GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Development of TGF-beta antagonists for cancer therapy

$619,633
Lalage Wakefield · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Development and validation of an autologous mouse model for the study of immune interactions with glioblastoma

$619,628
Zev Ari Binder · University Of Pennsylvania · R37 · FY2024 · CA

Mechanisms of BET bromodomain metabolic reprogramming in triple negative breast cancer

$619,610
Gerald V Denis · Boston University Medical Campus · R01 · FY2021 · CA

RNAi screen for chromatin modifiers in DNA repair and aging

$619,591
Philipp Oberdoerffer · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Novel Hyperpolarized MR Markers of Advanced Prostate Cancer Therapy

$619,505
John Kurhanewicz · University Of California, San Francisco · R01 · FY2015 · CA

MOLECULAR DISSECTION OF SEIZURE MICROENVIRONMENT IN MALIGNANT GLIOMA

$619,488
Jeffrey Noebels · Baylor College Of Medicine · R01 · FY2022 · CA

Tailoring CAR T cell therapy for Hodgkin Lymphoma

$619,470
Barbara Savoldo · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA

Neural Activity Signatures of Tumor Infiltration in the Human Brain

$619,470
Angelique C Paulk · Massachusetts General Hospital · R01 · FY2024 · NS

Modulation of Epigenetic Target in the Bone to Treat Breast Cancer Metastasis

$619,441
Han Xiao · Rice University · R01 · FY2024 · CA

Preclinical Testing of Targeted Therapies for Neurofibromas

$619,319
David W. Clapp · Indiana University Indianapolis · U01 · FY2009 · NS

A NOVEL MICROFLUIDIC DEVICE FOR SELECTION AND OPTIMIZATION OF DRUG DELIVERY VEHIC

$619,304
Balabhaskar Prabhakarpandian · Cfd Research Corporation · R44 · FY2013 · CA

CPMV-Polymer Devices to Enhance the Outcomes of Intratumoral Immunotherapy

$619,294
Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2024 · CA

Uncovering the Molecular Determinants of Metastatic Recurrence and Impaired NK Cell Function

$619,279
Srinivas Malladi · Ut Southwestern Medical Center · R01 · FY2024 · CA

Patho-Genetic Analysis of Invasive Mucinous Adenocarcinoma of the Lung

$619,255
Yutaka Maeda · Cincinnati Childrens Hosp Med Ctr · R01 · FY2022 · CA

Patho-Genetic Analysis of Invasive Mucinous Adenocarcinoma of the Lung

$619,253
Yutaka Maeda · Cincinnati Childrens Hosp Med Ctr · R01 · FY2023 · CA

Engineering Native E. coli to Detect, Report, and Treat Colorectal Cancer

$619,234
Amir Zarrinpar · University Of California, San Diego · U01 · FY2022 · CA

Probabilistic Multiscale Modeling of the Tumor Microenvironment

$619,118
Wesley Tansey · Sloan-Kettering Inst Can Research · R37 · FY2024 · CA

NOX family NADPH oxidases: roles in innate immunity and inflammatory disease

$619,098
Thomas Leto · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI

Single cell characterization of the biomaterial immune and stromal response

$618,965
Jennifer Hartt Elisseeff · Johns Hopkins University · R01 · FY2020 · EB

MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer

$618,912
Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2021 · CA

Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer

$618,854
Emese Zsiros · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA

Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments.

$618,825
Alain Charest · Beth Israel Deaconess Medical Center · R01 · FY2024 · CA

Targeting cellular senescence to inhibit the development and progression of ovarian endometriomas

$618,771
Shannon Michelle Hawkins · Indiana University Indianapolis · R01 · FY2025 · HD

Using the IL-1R1 and its ligands to optimize the T cell immune response to cancer

$618,713
Thomas S. Kupper · Brigham And Women'S Hospital · R01 · FY2023 · CA

AI enhanced lifetime-based mesoscopic in vivo imaging of tissue molecular heterogeneity

$618,698
Xavier Intes · Rensselaer Polytechnic Institute · R01 · FY2024 · CA